Dr. Hastings was trained with a background in nutrition, oxidative toxicology and biochemistry specializing in protein chemistry and enzymology. The focus of her research has been investigating free radical formation and oxidative mechanisms associated with neurodegeneration as they relate to models of Parkinson’s disease and drugs of abuse, utilizing both animal and cellular models. Dopamine oxidation to reactive metabolites, protein modification, and the effect of the reactive dopamine quinone on mitochondrial function has been the specific focus of the Hastings’ lab. More recently, her laboratory has been investigating the neuroprotective role of selenoproteins in Parkinson’s disease.
Education & Training
- MS, Pennsylvania State University, Biochemical Toxicology
- PhD, Medical College of Ohio (Univ. Toledo School of Medicine), Biochemistry
- Post Doc, University of Pittsburgh, Neurochemistry
Specialized Areas of Clinical, Research and/or Educational Interests
- Research: Oxidative mechanisms in Neurodegeneration; Parkinson’s disease; Mitochondrial dysfunction; Selenoproteins
- Education: Cell & Molecular Neurobiology, Protein chemistry, Nutrition, Career development
Professional Organization Membership
- Society for Neuroscience
- American Academy for Advancement of Science
- International Society for Neurochemistry
- Society for Free Radicals in Biology and Medicine
- American Chemical Society
Honors & Awards
- Robert H. and Lynnie Spahn Lectureship, Oklahoma Medical Research Foundation
- Faculty Fellow, University Honors College (45 selected out of ~4,500 faculty)
Zharikov, A., Cannon, J.R., Tapias, V., Bai, Q., Horowitz, M., Shah, V., El Ayadi, A., Hastings, T.G., Greenamyre, J.T., Burton, E.A. shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson’s disease model. J. Clinical Investigation 125 (7): 2721-35, doi: 10.1172/JCI64502, 2015.
Van Laar V.S., Berman S.B., Hastings T.G. Mic60/mitofilin overexpression alters mitochondrial dynamics and attenuates vulnerability of dopaminergic cells to dopamine and rotenone. Neurobiol Dis. 91:247-61, 2016.
Di Maio, R., Barrett P.J., Hoffman, E.K., Barrett, C.W., Zharikov, A., Borah, A., Hu, X., McCoy, J., Chu, C.T., Burton, E.A., Hastings, T.G., Greenamyre, J.T. (2016) α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease. Sci Transl Med. 8(342):342ra78. doi: 10.1126/scitranslmed.aaf3634., 2016.
Di Maio, R., Hoffman,E.K., Rocha, E.M., Keeney, M.T., Sanders, L.H., De Miranda, B.R., Zharikov, A., Van Laar, A., McCoy, J. Stepan, A.F., Lanz, T.A., Kofler, J.K., Burton, E.A., Alessi, D.R., Hastings, T.G., Greenamyre, J.T. (2018) LRRK2 activation in idiopathic Parkinson Disease. Science Translational Medicine 10, eaar5429., 2018
Rocha EM, De Miranda BR, Castro S, Drolet R, Hatcher NG, Yao L, Smith SM, Keeney MT, Di Maio R, Kofler J, Hastings TG, Greenamyre JT. LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease. Neurobiol Dis. 2020 Feb;134:104626. doi: 10.1016/j.nbd.2019.104626., 2020